Research programme: mitochondria-derived peptides - CohBar

Drug Profile

Research programme: mitochondria-derived peptides - CohBar

Alternative Names: CB-4209; Humanin - CohBar; MBTs - CohBar; MDPs - CohBar; Mitochondria-based therapeutics - CohBar; MOTS-c; MOTS-c analog - CohBar; SHLP 2; SHLP 6; Small humanin-like peptides - CohBar

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Albert Einstein College of Medicine; University of Southern California
  • Developer Albert Einstein College of Medicine; CohBar; University of Southern California
  • Class Antihyperglycaemics; Antineoplastics; Cardiovascular therapies; Hepatoprotectants; Hormones; Neuroprotectants; Obesity therapies; Peptides
  • Mechanism of Action AMP activated protein kinase stimulants; Angiogenesis inhibitors; Apoptosis stimulants; Insulin receptor modulators; Lipolysis-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Obesity; Prostate cancer; Type 2 diabetes mellitus
  • Research Alzheimer's disease; Atherosclerosis; Cancer; Cerebral ischaemia; Myocardial ischaemia; Neurodegenerative disorders

Most Recent Events

  • 02 Apr 2018 CohBar plans a phase Ia/Ib trial for Obesity in mid-2018
  • 23 Nov 2017 Pharmacodynamics data from a preclinical studies in Nonalcoholic Steatohepatitis and Obesity presented at the at 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD- 2017)
  • 23 Oct 2017 Pharmacodynamic data from preclinical studies in Non-alcoholic steatohepatitis released by CohBar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top